NCT07135323招募中不适用
AvertD Post-Approval Study
Prescient Medicine Holdings, Inc.1 个研究点 分布在 1 个国家目标入组 4,000 人开始时间: 2024年11月15日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 4,000
- 试验地点
- 1
- 主要终点
- Sensitivity and Specificity of AvertD
研究概览
简要总结
A Prospective Post-Approval Study of AvertD to Evaluate Device Performance, Prescribing Impact, and Labeling Comprehension in the Intended Use Population
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •≥18 years of age
- •Prior to first opioid prescription
- •Being considered for first oral opioid prescription (4-30 days)
- •Prescribed AvertD as part of care
- •Willing and able to complete yearly assessments for 5 years
- •Signed informed consent
排除标准
- •Planned opioid prescription <4 or >30 days
- •Any condition making participation unsafe or infeasible per investigator judgment
结局指标
主要结局
Sensitivity and Specificity of AvertD
时间窗: Measured over 5 years
Comparison of Averted results to diagnosis of Opioid Used Disorder from M.I.N.I. tool
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
China ADVATE PTP StudyHemophilia ANCT02170402Baxalta now part of Shire82
已完成
4 期
A Study of ADVATE in People With Hemophilia A in IndiaHemophilia ANCT04985682Baxalta now part of Shire50
Unknown
不适用
Adaprev in Digital Flexor Tendon RepairTendon InjuriesNCT01014494Renovo44
暂停
不适用
Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I DisorderAgitation,PsychomotorNCT03513549Alexza Pharmaceuticals, Inc.10,000
尚未招募
Unknown
Randomized Controlled Trials Based on Patient Willingness for Treating Rheumatoid Arthritis with Tibetan MedicineITMCTR2023000062Tibetan Hospital of Xizang Autonomous Region
